

RE: FOR YOUR REVIEW: Updated KM on COVID-19 Research Investments

From: "Lewis, James (IC)" <james.lewis@canada.ca>
To: "Paquet, Ann-Marie (IC)" <ann-marie.paquet@canada.ca>, "Roach, Elizabeth (IC)" <elizabeth.roach@canada.ca>, "Bildstein, Taylor (IC)" <taylor.bildstein@canada.ca>
Cc: SCMS-Parliamentary Affairs / Affaires-parlementaires-SCSM (IC) <ic.scms-parliamentaryaffairs-affaires-parlementaires-scsm.ic@canada.ca>, "Gennaro, Miriam (IC)" <miriam.gennaro@canada.ca>
Date: Mon, 28 Sep 2020 15:26:02 +0000
Attachment s: MISI_KM_COVID-19 Research Investments_EN_edits_Sept28.docx (37.77 kB)

Hi Ann-Marie, the entire KM document is really owned by SCMS – that’s why when we disagree with Sector’s wording and have to tighten or plain-language it, we inform them we’ve done so rather than seek their permission. That said, if there are complex policy positions in the document that SCMS teams would feel uncomfortable changing, we would go back to Sector for that certainly.

Since this is a simple fact-check, hopefully we can take care of this here rather than take up more time going back to Sector. If you feel you don’t have the answers, let us know and we can reach out. We have amended to include mention of GlaxoSmithKline (sp.).

James Lewis

Manager, Ministerial and Media Services
Innovation, Science and Economic Development Canada / Government of Canada
james.lewis@canada.ca / Tel: 613-720-2717 / TTY: 1-866-694-8389

Gestionnaire, Services ministériels et médiatiques
Innovation, Sciences et Développement économique Canada / Gouvernement du Canada
james.lewis@canada.ca / Tél. : 613-720-2717 / ATS : 1-866-694-8389

From: Paquet, Ann-Marie (IC) <ann-marie.paquet@canada.ca>
Sent: September 28, 2020 11:00 AM
To: Roach, Elizabeth (IC) <elizabeth.roach@canada.ca>; Bildstein, Taylor (IC) <taylor.bildstein@canada.ca>
Cc: SCMS-Parliamentary Affairs / Affaires-parlementaires-SCSM (IC) <ic.scms-parliamentaryaffairs-affaires-parlementaires-scsm.ic@canada.ca>; Lewis, James (IC) <james.lewis@canada.ca>
Subject: RE: FOR YOUR REVIEW: Updated KM on COVID-19 Research Investments

Hi Elizabeth,

Given the change was made to the background section, I would think you would want to ask Sector to approve as that would be their content.

However, I have reviewed and made a small adjustment. According to the NR, the agreement with Sanofi is actually with Sanofi and GlaxoSmithKlyne

<https://www.canada.ca/en/public-services-procurement/news/2020/09/government-of-canada-signs-new-agreements-to-secure-additional-vaccine-candidate-and-treatment-for-covid-19.html>

Regards,

Ann Marie

Ann Marie Paquet

A/Communications Manager, Strategic and Advisory Services
Strategic Communications and Marketing Sector
Innovation, Science and Economic Development Canada / Government of Canada
ann-marie.paquet@canada.ca / Cel: 343-550-1521

Gestionnaire des communications p.i., Services stratégiques et consultatifs
Secteur des communications stratégiques et du marketing
Innovation, Sciences et Développement économique Canada / Gouvernement du Canada
ann-marie.paquet@canada.ca / Tél. cell. : 343-550-1521

From: Roach, Elizabeth (IC) <elizabeth.roach@canada.ca>

Sent: September 28, 2020 10:48 AM

To: Paquet, Ann-Marie (IC) <ann-marie.paquet@canada.ca>; Bildstein, Taylor (IC) <taylor.bildstein@canada.ca>

Cc: SCMS-Parliamentary Affairs / Affaires-parlementaires-SCSM (IC) <ic.scms-parliamentaryaffairs-affaires-parlementaires-scsm.ic@canada.ca>; Lewis, James (IC) <james.lewis@canada.ca>

Subject: FOR YOUR REVIEW: Updated KM on COVID-19 Research Investments

Hello Ann Marie and Taylor,

The last paragraph in the background section of the KM on COVID-19 Research Investments needed updating.

We've attempted to make that change on our end (tracked in the attached), but could we please have your review to ensure it's complete and up-to-date before it goes to Vicky for approval?

Thank you,
Elizabeth

Elizabeth Roach
Parliamentary Affairs Communications Advisor
Ministerial and Media Services
Innovation, Science and Economic Development Canada / Government of Canada
elizabeth.roach@canada.ca | Tel: 343-548-6649